5-Amino-1MQ vs BPC-157
preclinical vs Extensively Studied
compatible No known interactions; different mechanisms with potential complementary benefits.
Molecular Data
5-Amino-1MQ BPC-157
Weight — 1,419.53 Da
Half-life 4-7 hours (3.8h IV, 6.9h oral) <30 minutes
Chain — 15 amino acids
Type Small molecule NNMT enzyme inhibitor Pentadecapeptide
Key Benefits
5-Amino-1MQ
01 Enhanced NAD+ levels
02 Improved mitochondrial function
03 Better energy metabolism
04 Enhanced cellular repair
05 Improved insulin sensitivity
06 Longevity support
07 Convenient daily oral dosing
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Dosing Protocols
5-Amino-1MQ
50-100mg oral or 150-500mcg SubQ / Once daily, preferably morning
Conservative starting (mcg protocol) 150-250mcg 1x daily
Conservative standard (mcg protocol) 250-500mcg 1x daily
Study-based (mg protocol) ~350mg (5mg/kg) 1x daily
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Side Effects
5-Amino-1MQ
Generally minimal side effects
Occasional mild GI adjustment
Potential sleep interference if dosed late in day
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Contraindications
Pregnancy or breastfeeding
Pre-existing metabolic conditions (consult healthcare provider)
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Research Evidence
5-Amino-1MQ BPC-157
Status preclinical Extensively Studied
References 3 studies 6 studies
Latest March 2024 January 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.